رسالة جامعية
(1) 痰細胞化生之流行病學調查 (2) 嚴重急性呼吸道症候群死亡之血液生化預測因子 ; (1) Epidemiology of sputum metaplasia (2) Hematological and Biochemical Factors in Predicting SARS Fatality in Taiwan
| العنوان: | (1) 痰細胞化生之流行病學調查 (2) 嚴重急性呼吸道症候群死亡之血液生化預測因子 ; (1) Epidemiology of sputum metaplasia (2) Hematological and Biochemical Factors in Predicting SARS Fatality in Taiwan |
|---|---|
| المؤلفون: | 張筱玲, Chang, Hsiao-Ling |
| المساهمون: | 宋鴻樟, 臺灣大學：環境衛生研究所 |
| سنة النشر: | 2005 |
| المجموعة: | National Taiwan University Institutional Repository (NTUR) |
| مصطلحات موضوعية: | (1) 肺癌, 痰檢體, 細胞化生, 廚師, 吸菸, 油煙 (2) 嚴重急性呼吸道症候群, 致死, C-反應蛋白質, 淋巴球減少症, 乳酸脫氫酶, 呼吸困難, (1) Lung cancer, Sputum, Metaplasia, Cooking oil fume, Smoking (2) Severe acute respiratory syndrome (SARS), Fatality, C-reactive protein, Lymphopenia, Lactic acid dehydrogenase, Dyspnea |
| الوصف: | (1) 痰細胞化生之流行病學調查 民國80~82年國人的肺癌死亡率相當於發生率，但自83年起，死亡率增加的趨勢大於發生率，顯示肺癌不易被診斷。肺部疾病（包括肺癌）與暴露於二手菸及炒菜油煙之環境等因子相關，本研究即為探討大台北地區民眾痰細胞化生盛行率及其危險因子，進而瞭解餐飲業者健康狀況及痰細胞化生盛行情形。 本研究於2000年至2001年在大台北地區包括基隆市、台北市及台北縣三縣市，以自願方式收集研究對象。利用橫斷研究法進行問卷調查、健康檢查（包括胸部X光檢查）及痰檢體收集，並進行細胞學檢驗。 共收集513位的有效檢體，包括基隆市158位、台北市130位及台北縣225位，其中185位有痰細胞化生現象，328位無痰細胞化生現象。發現有痰細胞化生現象者較年輕，健康狀況亦較好，但是目前仍有吸菸的盛行率較高，為無痰細胞化生者的1.4倍（p=0.046）。在控制年齡、性別、籍貫、教育程度及吸菸習慣情形後，發現不論是全部研究對象、或是吸菸者、或是烹調者，在家中烹調因子均與痰細胞化生間具有統計顯著性，尤其是吸菸者有烹調行為，且每週下廚至少4天及以上者發生痰細胞化生現象之危險性竟高達7.6倍（95%信賴區間為1.5~39.2），故具有油煙暴露及吸菸者會有較高的痰細胞化生情形。另目前仍吸菸者發生痰細胞化生的危險性是已戒菸者與不吸菸者的1.7~1.9倍，而已戒菸者與不吸菸者發生痰細胞化生的危險性差不多，顯示吸菸行為與痰細胞化生有關。吸菸者除了在家中烹調因子外，吸菸時未使用濾嘴及有肺氣腫疾病者，發生痰細胞化生之危險性各達3.5倍及5.8倍。 因每週在家中下廚至少會有4天及以上者與痰細胞化生現象之相關均達統計顯著意義，故自研究對象中選取工作地點在台北縣、市之餐飲業者59人及社區民眾126人，進一步探討餐飲業者與社區居民生活型態、健康狀況及痰細胞學檢驗結果之相關。餐飲業者較社區民眾年輕，大多為女性，其教育程度與目前吸菸習慣均較低，但健康狀況較好。餐飲業者除了在工作上會暴露在油煙的環境下外，在家中亦較社區民眾有較多的機會暴露在油煙的環境下。 餐飲業者及社區民眾痰細胞化生盛行率差不多。若將餐飲業者以工作性質細分為廚師、餐務處理者及外場行政者，其中廚師約13.3%有肺部鈣化現象是值得注意的。雖然痰細胞化生盛行率在三組間之差異不具統計意義，但仍以廚師痰細胞化生盛行率最高約為45.0%，是外場行政者36.4%的1.2倍，比餐務處理者23.5%的1.9倍顯著。 本研究結果顯示家中烹調情形及吸菸習慣與發生痰細胞化生現象之相關性強。建議改變烹調行為及吸菸習慣，可能降低發生痰細胞化生的危險性。 (2) 嚴重急性呼吸道症候群死亡之血液生化預測因子 嚴重急性呼吸道症候群全球致死率為10.9%。本研究探討台灣嚴重急性呼吸道症候群病例在流行病學、臨床徵候及臨床檢驗值之死亡預後因子。由於血漿C-反應蛋白質（C-reactive protein，CRP）與發炎有關，亦探討CRP值與有無呼吸困難及存活間之關係。 研究對象以台灣地區自2003年3月14日至6月15日通報至傳染病監視通報系統之資料，並經SARS之冠狀病毒相關檢驗分析方法檢出陽性結果者為主，共有346例SARS確定病例。蒐集病患之基本資料、入院時臨床徵候及臨床檢驗初始資料，整理後進行分析。 結果顯示SARS病患有高的初始CRP值及低的初始淋巴球（lymphocyte）數，SARS死亡者（n=73或21.1%）之CRP平均值為47.7 mg/L比存活者的24.6 mg/L高（p=0.0001）。而死亡者之淋巴球數平均值為814 /mL比存活者的1019 / /mL低(p=0.004)。在探討SARS死亡預測因子之多變項分析時，於控制年齡及性別因子後，病患初始中性球數在7000 /mL以上者死亡的勝算比是7000 /mL 以下者的6.4倍（95%信賴區間為1.1~36.0）。其他具有統計顯著意義之死亡預測因子有初始CRP值大於47.5 mg/L者（5.8倍）及初始乳酸脫氫酶（lactic acid dehydrogenase，LDH）大於593.5 IU/L者（4.2倍）。另SARS病患具有慢性阻塞性肺疾病、腦中風或心臟病之一者，有高的初始CRP值，約61.5 mg/L。在控制年齡及性別因子下，發現有呼吸困難死亡者、有呼吸困難存活者及沒有呼吸困難死亡者，發生CRP值大於47.5mg/L之勝算比各為沒有呼吸困難存活者的6.0倍（95%信賴區間為1.8~20.3）、3.5倍（95%信賴區間為1.3~9.0）及2.8倍（95%信賴區間為1.0~7.4），其差異均具有統計顯著意義。 高初始中性球數、高初始CRP值及高初始LDH濃度是SARS死亡的重要預測因子。其中初始CRP值不僅僅為死亡預測因子，亦是嚴重感染SARS冠狀病毒的一個很好的預測因子。 ; (1) Epidemiology of sputum metaplasia ... |
| نوع الوثيقة: | thesis |
| وصف الملف: | 716110 bytes; application/pdf |
| اللغة: | Chinese English |
| العلاقة: | (1) 痰細胞化生之流行病學調查 1.行政院衛生署：中華民國癌症登記，行政院衛生署編印，民國八十年~八十五年。 2.行政院衛生署：中華民國衛生統計（一），行政院衛生署編印，民國八十年~八十九年。 3.行政院衛生署：中華民國癌症登記，行政院衛生署編印，民國六十八年~七十九年。 4.行政院衛生署：中華民國七十七年~八十一年衛生統計（二），行政院衛生署編印，民國七十八年~八十二年。 5.Ko YC, Lee CH, Chen MJ, Huang CC, et al: Risk factors for primary lung cancer among non-smoking women in Taiwan. Int J Epidemiol 1997;26(1):24-31. 6.Ger LP, Hsu WL, Chen KT, Chen CJ: Risk factors of lung cancer by histological category in Taiwan. Anticancer Res 1993;13(5A):1491-500. 7.Ger LP, Liou SH, Shen CY, Kao SJ, et al: Risk factors of lung cancer. J Formos Med Assoc 1992;91(Suppl 3):S222-31. 8.Liu Q, Sasco AJ, Riboli E, Hu MX: Indoor air pollution and lung cancer in Guangzhou, People’s Republic of China. Am J Epidemiol 1993;137(2):145-54. 9.Liu ZY, He XZ, Chapman RS: Smoking and other risk factors for lung cancer in Xuanwei, China. Int J Epidemiol 1991;20(1):26-31. 10.Gao YT, Blot WJ, Zheng W, Ershow AG, et al: Lung cancer among Chinese women. Int J Cancer 1987;40(5):604-9. 11.Pawlega J, Rachtan J, Dyba T: Evaluation of certain risk factors for lung cancer in Cracow（Poland）－A case-control study. Acta Oncol 1997;36(5):471-6. 12.He XZ, Chen W, Liu ZY, Chapman RS: An epidemiological study of lung cancer in Xuan Wei County, China: current progress. Case-control study on lung cancer and cooking fuel. Environ Health Persp 1991;94:9-13. 13.MacLennan R, Da Costa J, Day NE, Law CH, et al: Risk factors for lung cancer in Singapore Chinese, a population with high female incidence rates. Int J Cancer 1977;20(6):854-60. 14.Wu AH, Yu MC, Thomas DC, Pike MC, Henderson BE: Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. Cancer Res 1988;48:7278-84. 15.Wu AH, Henderson BE, Pike MC, Yu MC: Smoking and other risk factors for lung cancer in women. JNCI 1985;74:747-51. 16.台灣菸酒公賣局：台灣地區菸酒市場調查總報告，台灣菸酒公賣局編印，民國八十五年。 17.Salomaa ER, Liippo K, Taylor P, Palmgren J, et al: Prognosis of patients with lung cancer found in a single chest radiograph screening. Chest 1998;114:1514-8. 18.Montuenga LM, Zhou J, Avis I, Vos M, et al: Expression of heterogeneous nuclear ribonucleoprotein A2/B1 changes with critical stages of mammalian lung development. Am J Resp Cell Mol 1998;19:554-62. 19.Tockman MS, Gupta PK, Myers JD, Frost JK, et al: Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection. J Clin Oncol 1988;6(11):1685-1693. 20.Tockman MS: Clinical detection of lung cancer progression markers. J Cell Biochem 1996;25S:177-84. 21.Tockman MS, Mulshine JL, Piantadosi S, Erozan YS, et al: Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin Cancer Res 1997;3:2237-46. 22.Qiao YL, Tockman MS, Erozan YS, Yao SX, et al: A case-control study of an early biomarker of lung cancer in a screening cohort of Yunnan Tin Miners in China. Cancer Epidemiol Biomarkers Prev 1997;6(11):893-900. 23.許榮譯：癌細胞遺傳學，醫學心理衛生叢書，水牛出版社印行，民國八十三年。 24.Ronai Z, Yabubovskaya MS, Zhang E, Belitsky GA: K-ras mutation in sputum of patients with or without lung cancer. J Cell Biochem 1997;25S:172-6. 25.Yakubovskaya MS, Spiegelman V, Luo FC, Malaev S, et al: High frequency of K-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer. Int J Cancer 1995;63:810-4. 26.Mills NE, Fishman CL, Scholes J, Anderson SE, et al: Detection of K-ras oncogene mutation in bronchoalveolar lavage fluid for lung. J Natl Cancer I 1995;87(14):1056-60. 27.Bos JL: Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9. 28.Westra WH, Slebos RJC, Offerhaus GJA, Goodman SN, et al: K-ras oncogene activation in lung adenocarcinomas from former smokers. Cancer 1993;72:432-8. 29.Mao L, Hruban RH, Boyle JO, Tockman M, et al: Detection of oncogene mutation in sputum precedes diagnosis of lung cancer. Cancer Res 1994;54:1634-7. 30.Shiono S, Omoe K, Endo A: K-ras gene mutation in sputum samples containing atypical cells and adenocarcinoma cells in the lung. Carcinogenesis 1996;17(8):1683-6. 31.Wang YC, Lee HS, Chen SK, Yang SC, et al: Analysis of K-ras gene mutations in lung carcinomas: correlation with gender, histological subtypes, and clinical outcome. J Cancer Res Clin 1998;124(9): 517-22. 32.Gao HG, Chen JK, Stewart J, Song B, et al: Distribution of p53 and K-ras mutation in human lung cancer tissues. Carcinogenesis 1997;18(3):473-8. 33.Husgafvel-Pursiainen K, Hackman P, Ridanpää M, Anttila S, et al: K-ras mutation in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos. Int J Cancer 1993;53:250-6. 34.Suzuki Y, Orita M, Shiraishi M, Hayashi K, et al: Detaction of ras gene mutation in human lung cancer by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1990;5:1037-43. 35.黃明賢編譯：肺癌細胞診斷－型態及其臨床，台灣長年出版社印行，民國八十六年。 36.Saccomanno G, et al: Development of carcinoma of the lung as reflected in exfoliated cells. Cancer 1974;33:256-70. 37.Nasiell M, et al: Metaplasia and atypical metaplasia in the bronchial epithelium － A histopathologic and cytopathologic study. Acta Cytol 1966;10:421-27. 38.Tockman MS: Clinical detection of lung cancer progression markers. J Cell Biochem 1996;25(suppl):177-84. 39.Vine MF, Schoenbach VJ, Hulka BS, Koch GG, et al: Atypical metaplasia and incidence of bronchogenic carcinoma. Am J Epidemiol 1990;131(5):781-93. 40.Roby TJ, Swan GE, Sorensen KW, Hubbard GA, et al: Discriminant analysis of lower respiratory tract components associated with cigarette smoking, based on quantitative sputum cytology. Acta Cytol 1990;34(2):147-54. 41.Le Marchand L, Hankin JH, Bach F, Kolonel LN, et al: An ecological study of diet and lung cancer in the South Pacific. Int J Cancer 1995;63(1):18-23. 42.Carstensen JM, Wicksell L, Eklund G, Gustafsson JA: Lung cancer incidence among Swedish bakers and pastrycook: temporal variation. Scand J Soc Med 1988;16(2):81-5. 43.Liu ZY, He XZ, Chapman RS: Smoking and other risk factors for lung cancer in Xuanwei, China. Int J Epidemiol 1991;20(1):26-31 44.Ko YC, Lee CH, Chen MJ, Huang CC, et al: Risk factors for primary lung cancer among non-smoking women in Taiwan. Int J Epidemiol 1997;26(1):24-31. 45.Kjaerheim K, Andersen A: Incidence of cancer among male waiters and cook: two Norwegian cohorts. Cancer Causes Control 1993;4(5):419-26. 46.Ger LP, Hsu WL, Chen KT, Chen CJ: Risk factors of lung cancer by histological category in Taiwan. Anticancer Res 1993;13(5A):1491-500. 47.Ger LP, Liou SH, Shen CY, Kao SJ, et al: Risk factors of lung cancer. J Formos Med Assoc 1992;91(Suppl 3):S222-31. 48.葛應欽、李建宏、姜泰安、王美珍等：不吸菸婦女肺癌研究，生命科學簡訊，民國八十八年，第十三卷第四期，第12至15頁。 49.Coggon D, Wield G: Mortality of army cooks. Scand J Work Environ Health 1993;19(2):85-8. 50.Siegel M: Involuntary smoking in the restaurant workplace. A review of employee exposure and health effects. JAMA 1993;270(4):490-3. 51.Leigh JP: Occupations, cigarette smoking, and lung cancer in the epidemiological follow-up to the NHANES I and the California Occupational Mortality Study. Bull N Y Acad Med 1996;73(2):370-97. 52.Andersen A, Bjelke E, Langmark F: Cancer in waiters. Br J Cancer 1989;60(1):112-5. 53.Kjaerheim K, Andersen A: Cancer incidence among waitresses in Norway. Cancer Causes Control 1994;5(1):31-7. 54.Costantini AS, Pirastu R, Lagorio S, Miligi L, et al: Studying cancer among female workers: methods and preliminary results from a record-linkage system in Italy. J Occup Med 1994;36(11):1180-6. 55.Jahn I, Ahrens W, Bruske-Hohlfeld I, Kreuzer M, et al: Occupational risk factors for lung cancer in women: results of a case-control study in Germany. Am J Ind Med 1999;36(1):90-100. 56.Kennedy TC, Proudfoot SP, Franklin WA, Merrick TA, et al: Cytopathological analysis of sputum in patients with airflow obstruction and significant smoking histories. Cancer Res 1996;56(20):4673-8. 57.翁鵬傑、彭俊明、陳玉燕等人編譯：哈伯氏生物化學（上冊），第22版，藝軒圖書出版社印行，民國八十二年，第186頁與261頁。 58.Löfroth G. Airborne mutagens and carcinogens from cooking and other food preparation processes. Toxicol Lett 1994;72:83-6. 59.Salmon CP, Knize MG, Felton JS. Effects of marinating on heterocyclic amine carcinogen formation in grilled chicken. Food Chem Toxicol 1997;35(5):433-41. 60.Berg I, Övervik E, Nord CE, Gustafsson JA. Mutagenic activity in smoke formed during broiling of lean pork at 200, 250, and 300℃. Mutat Res 1988;207:199-204. 61.Rappaport SM, McCartney MC, Wei ET. Volatilization of mutagens from beef during cooking. Cancer Lett 1979;8(2):139-45. 62.Chiang TA, Wu PF, Wang LF, Lee H, Lee CH, Ko YC. Mutagenicity and polycyclic aromatic hydrocarbon content of fumes from heated cooking oils produced in Taiwan. Mutat Res 1997;381(2):157-61. 63.Chiang TA, Wu PF, Ko YC. Prevention of exposure to mutagenic fumes produced by hot cooking oil in Taiwanese kitchens. Environ Mol Mutagen 1998;31(1):92-6. 64.Li S, Pan D, Wang G. Analysis of polycyclic aromatic hydrocarbons in cooking oil fumes. Arch Environ Health 1994;49(2):119-22. 65.Wu PF, Chiang TA, Wang LF, Chang CS, Ko YC. Nitro-polycyclic aromatic hydrocarbon contents of fumes from heated cooking oils and prevention of mutagenicity by catechin. Mutat Res 1998;403(1-2):29-34. 66.Teschke K, Hertzman C, Van Netten C, Lee E, Morrison B, Cornista A, et al. Potential exposure of cooks to airborne mutagens and carcinogens. Environ Res 1989;50:296-308. 67.Shields PG, Xu GX, Blot WJ, Fraumeni JF, Trivers GE, Pellizzari ED, et al. Mutagens from heated Chinese and U.S. cooking oils. J Natl Cancer Inst 1995;87(11):836-41. 68.Yang CC, Jenq SN, Lee H. Characterization of the carcinogen 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in cooking aerosols under domestic conditions. Carcinogenesis 1998;19(2):359-63. 69.Hemminki K, Pershagen G: Cancer risk of air pollution: epidemiological evidence. Environ Health Perspect 1994;102(s4):187-92. 70.Rusin M, Butkiewicz D, Malusecka E, Zborek A, et al: Molecular epidemiological study of non-small-cell lung cancer from an environmentally polluted region of Poland. Br J Cancer 1999;80(9):1445-52. 71.Carnow BW, Meier P: Air pollution and Pulmonary cancer. Arch Environ Health 1973;27:207-18. 72.Engholm G, Palmgren F, Lynge E: Lung cancer, smoking, and environment: a cohort study of the Danish population. BMJ 1996;312:1259-63. 73.Thunnissen FBJM: Sputum examination for early detection of Lung cancer. J Clin Pathol 2003;56(11):805-10. 74.Kennedy TC, Miller Y, Prindiville S: Screening for Lung Cancer Revisited and the Role of Sputum Cytology and Fluorescence Bronchoscopy in a High-Risk Group. Chest 2000;117(4) (Suppl):72S-79S. (2) 嚴重急性呼吸道症候群死亡之血液生化預測因子 1.World Health Organization: Summary table of areas that experienced local transmission of SARS during the outbreak period from 1 November 2002 to 31 July 2003. [Accessed November 21, 2003.] Available at: ttp://www.who.int/csr/sars/areas/areas2003_11_21/en/. 2.World Health Organization: Update 95－SARS: Chronology of a serial killer. [Accessed July 4, 2003.] Available at: http://www.who.int/csr/don/2003_07_04/en/print.htmlTest. 3.Low DE, McGeer A: SARS－One year later. N Engl J Med 2003;349(25):2381-2. 4.Centers for Disease Control and Prevention: Information for SARS patients and their close contacts. [Accessed August 19, 2003.] Available at: http://www.cdc.gov/ncidod/sars/factsheetcc.htmTest. 5.World Health Organization: Severe acute respiratory syndrome (SARS)－Multi-country outbreak-Update. [Accessed March 16, 2003.] Available at: http://www.who.int/csr/don/2003_03_16/en/print.htmlTest. 6.World Health Organization: World Health Organization issues emergency travel advisory. [Accessed March 15, 2003.] Available at: http://www.who.int/csr/sarsarchive/2003_03_15/en/print.htmlTest. 7.Centers for Disease Control and Prevention: Update: Outbreak of severe acute respiratory syndrome－Worldwide, 2003. MMWR 2003;52(12):241-8. 8.Tsang KW, Ho PL, Ooi GC, et al: A cluster of cases of severe respiratory syndrome in Hong Kong. N Engl J Med 2003;348(20):1977-85. 9.Centers for Disease Control and Prevention: Severe acute respiratory syndrome－Singapore, 2003. MMWR 2003;52(18):405-11. 10.Hsu LY, Lee CC, Green JA, et al: Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. EID 2003;9(6):713-7. 11.Lee N, Hui D, Wu A, et al: A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348(20):1986-94. 12.Abdullah ASM, Tomlinson B, Cockram CS, et al: Lessons from the severe acute respiratory syndrome outbreak in Hong Kong. EID 2003;9(9):1042-5. 13.Booth CM, Matukas LM, Tomlinson GA, et al: Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003;289(21):2801-9. 14.Twu SJ, Chen TJ, Chen CJ, et al: Control measures for severe acute respiratory syndrome (SARS) in Taiwan. EID 2003;9(6):718-20. 15.Centers for Disease Control and Prevention: Severe acute respiratory syndrome－Taiwan, 2003. MMWR 2003;52(20):461-6. 16.Guan Y, Zheng BJ, He YQ, et al: Isolation and Characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003;302:276-8. 17.Center for Disease Control, Department of Health, Executive Yuan, Taiwan: Memoir of severe acute respiratory syndrome control in Taiwan. Center for Disease Control, Department of Health, Executive Yuan, Taiwan. September 2003. 18.Donnelly CA, Ghani AC, Leung GM, et al: Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 2003;361:1761-6. 19.World Health Organization: Preliminary clinical description of severe acute respiratory syndrome. Available at: http://www.who.int/csr/sars/clinical/en/print.htmlTest. 20.Peiris JSM, Chu CM, Cheng VCC, et al: Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003;361:1767-72. 21.World Health Organization: Prospective study of the clinical progression and viral load of SARS associated coronavirus pneumonia in a community outbreak. Available at: http://www.who.int/csr/sars/prospectivestudy/en/print.htmlTest. 22.Chan PKS, To WK, Ng KC, et al: Laboratory diagnosis of SARS. EID 2004;10(5):825-31. 23.Tsang OTY, Chau TN, Choi KW, et al: Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. EID 2003;9(11):1381-87. 24.World Health Organization: WHO issues consensus document on the epidemiology of SARS. [Accessed October 17, 2003.] Available at: http://www.who.int/csr/sars/archiveTest/ epiconsensus/en/print.html. 25.Lew TWK, Kwek TK, Tai D, et al: Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA 2003;290(3):374-80. 26.Chan JWM, Ng CK, Chan YH, et al: Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax 2003;58:686-9. 27.Singh K, Hsu LY, Villacian JS, et al: Severe acute respiratory syndrome: Lessons from Singapore. EID 2003;9(10):1294-98. 28.Peiris JSM, Lai ST, Poon LLM, et al: Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003;361:1319-25. 29.Poutanen SM, Low DE, Henry B, et al: Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003;348(20):1995-2005. 30.Chan-Yeung M, Yu WC: Outbreak of severe acute respiratory syndrome in Hong Kong special administrative region: case report. BMJ 2003;326:850-2. 31.Rainer TH, Cameron PA, Smit DV, et al: Evaluation of WHO criteria for identifying patients with severe acute respiratory syndrome out of hospital: prospective observational study. BMJ 2003;326:1354-8. 32.Fowler RA, Lapinsky SE, Hallett D, et al: Critically ill patients with severe acute respiratory syndrome. JAMA 2003;290(3):367-73. 33.Tsui PT, Kwok ML, Yuen H, et al: Severe acute respiratory syndrome: clinical outcome and prognostic correlates. EID 2003;9(9):1064-9. 34.Wang RSM, Wu A, To KF, et al: Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ 2003;326:1358-62. 35.Wang JT, Sheng WH, Fang CT, et al: Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. EID 2004;10(5):818-24. 36.World Health Organization: Case definitions for surveillance of severe acute respiratory syndrome (SARS). [Accessed May 30, 2003.] Available at: http://www.who.int/csr/sarsTest/ casedefinition/en/. 37.World Health Organization: Alert, verification and public health management of SARS in the post-outbreak period. Available at: http://www.who.int/csr/sars/postoutbreak/en/print.htmlTest 38.World Health Organization: Summary of probable SARS cases with onset of illness from 1 November 2002 to 7 August 2003. [Accessed August 15, 2003.] Available at: http://www.who.int/csr/sars/country/enTest/ country2003_08_15.pdt. 39.Fischbach F: A Manual of Laboratory and Diagnostic Tests. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins. 2004. 40.Centers for Disease Control and Prevention. Use of quarantine to prevent transmission of severe acute respiratory syndrome－Taiwan, 2003. MMWR 2003;52:680-3. 41.Morley JJ, Kushner I: Serum C-reactive protein levels in disease. Ann NY Acad Sci 1982;389:406-18. 42.Montaner JS, Hawley PH, Ronco JJ, et al: Multisystem organ failure predicts mortality of ICU patients with acute respiratory failure secondary to AIDS-related PCP. Chest 1992;102(6):1823-8. 43.Quist J, Hill AR: Serum lactate dehydrogenase (LDH) in Pneumocystis carinii pneumonia, tuberculosis and bacterial pneumonia. Chest 1995;108(2):415-8. 44.Taina J, Jussi M, Pia T, et al: Clinical profile of serologically diagnosed pneumococcal pneumonia. Pediatr Infect Dis J 2001; 20:1028-33. 45.Kawasaki Y, Hosoya M, Katayose M, et al: Correlation between serum interleukin 6 and C-reactive protein concentrations in patients with adenoviral respiratory infection. Pediatr Infect Dis J 2002; 21:370-4. 46.Ruuskanen O, Meurman O, Sarkkinen H. Adenoviral diseases in children: a study of 105 hospital cases. Pediatrics 1985; 76:79-83. 47.Putto A, Meurman O, Ruuskanen O. C-reactive protein in the differentiation of adenoviral, Epstein-Barr viral and streptococcal tonsillitis in children. Eur J Pediatr 1986; 145:204-6. 48.Nicoll D, McPhee SJ, Pignone M: Pocket guide to diagnostic tests. 4th ed. Appleton & Lange: The McGraw-Hill Companies, Inc. 2004.; zh-TW; http://ntur.lib.ntu.edu.tw/handle/246246/59782Test; http://ntur.lib.ntu.edu.tw/bitstream/246246/59782/1/ntu-94-D85821008-1.pdfTest |
| الإتاحة: | http://ntur.lib.ntu.edu.tw/handle/246246/59782Test http://ntur.lib.ntu.edu.tw/bitstream/246246/59782/1/ntu-94-D85821008-1.pdfTest |
| رقم الانضمام: | edsbas.CD2184E1 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |